Top Key Companies for Oncology Radiopharmaceutical Market: Novartis, Chimeric Therapeutics Limited, Fusion Pharma, Lantheus Medical lmaging, Inc., NanoMab, NuView Life Sciences., PentixaPharm GmbHPrecirix, RadioMedix, RayzeBio, Telix Pharmaceuticals Limited, Theragnostics Ltd, Vect-Horus.
Global Oncology Radiopharmaceutical Market Size was estimated at USD 309.53 million in 2022 and is projected to reach USD 438.08 million by 2028, exhibiting a CAGR of 5.96% during the forecast period.
Global Oncology Radiopharmaceutical Market Overview And Scope:
The Global Oncology Radiopharmaceutical Market Report 2026 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Oncology Radiopharmaceutical utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2026 and 2035. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Oncology Radiopharmaceutical Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oncology Radiopharmaceutical portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oncology Radiopharmaceutical market.
Global Oncology Radiopharmaceutical Market Segmentation
By Type, Oncology Radiopharmaceutical market has been segmented into:
Oral Drugs
Intravenous Drugs
Other
By Application, Oncology Radiopharmaceutical market has been segmented into:
Hospitals and Clinics
Pharmaceutical Company
Research Center
Other
Regional Analysis of Oncology Radiopharmaceutical Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Oncology Radiopharmaceutical Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Oncology Radiopharmaceutical market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Oncology Radiopharmaceutical market.
Top Key Companies Covered in Oncology Radiopharmaceutical market are:
Novartis
Chimeric Therapeutics Limited
Fusion Pharma
Lantheus Medical lmaging
Inc.
NanoMab
NuView Life Sciences.
PentixaPharm GmbHPrecirix
RadioMedix
RayzeBio
Telix Pharmaceuticals Limited
Theragnostics Ltd
Vect-Horus
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Oncology Radiopharmaceutical Market by Type
5.1 Oncology Radiopharmaceutical Market Overview Snapshot and Growth Engine
5.2 Oncology Radiopharmaceutical Market Overview
5.3 Oral Drugs
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral Drugs: Geographic Segmentation
5.4 Intravenous Drugs
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Intravenous Drugs: Geographic Segmentation
5.5 Other
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Other: Geographic Segmentation
Chapter 6: Oncology Radiopharmaceutical Market by Application
6.1 Oncology Radiopharmaceutical Market Overview Snapshot and Growth Engine
6.2 Oncology Radiopharmaceutical Market Overview
6.3 Hospitals and Clinics
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2026-2035F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospitals and Clinics: Geographic Segmentation
6.4 Pharmaceutical Company
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2026-2035F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Pharmaceutical Company: Geographic Segmentation
6.5 Research Center
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2026-2035F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Research Center: Geographic Segmentation
6.6 Other
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2026-2035F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Oncology Radiopharmaceutical Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Oncology Radiopharmaceutical Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Oncology Radiopharmaceutical Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 NOVARTIS
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 CHIMERIC THERAPEUTICS LIMITED
7.4 FUSION PHARMA
7.5 LANTHEUS MEDICAL LMAGING
7.6 INC.
7.7 NANOMAB
7.8 NUVIEW LIFE SCIENCES.
7.9 PENTIXAPHARM GMBHPRECIRIX
7.10 RADIOMEDIX
7.11 RAYZEBIO
7.12 TELIX PHARMACEUTICALS LIMITED
7.13 THERAGNOSTICS LTD
7.14 VECT-HORUS
Chapter 8: Global Oncology Radiopharmaceutical Market Analysis, Insights and Forecast, 2026-2035
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Oral Drugs
8.2.2 Intravenous Drugs
8.2.3 Other
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospitals and Clinics
8.3.2 Pharmaceutical Company
8.3.3 Research Center
8.3.4 Other
Chapter 9: North America Oncology Radiopharmaceutical Market Analysis, Insights and Forecast, 2026-2035
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Oral Drugs
9.4.2 Intravenous Drugs
9.4.3 Other
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospitals and Clinics
9.5.2 Pharmaceutical Company
9.5.3 Research Center
9.5.4 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Oncology Radiopharmaceutical Market Analysis, Insights and Forecast, 2026-2035
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Oral Drugs
10.4.2 Intravenous Drugs
10.4.3 Other
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospitals and Clinics
10.5.2 Pharmaceutical Company
10.5.3 Research Center
10.5.4 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Oncology Radiopharmaceutical Market Analysis, Insights and Forecast, 2026-2035
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Oral Drugs
11.4.2 Intravenous Drugs
11.4.3 Other
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospitals and Clinics
11.5.2 Pharmaceutical Company
11.5.3 Research Center
11.5.4 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Oncology Radiopharmaceutical Market Analysis, Insights and Forecast, 2026-2035
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Oral Drugs
12.4.2 Intravenous Drugs
12.4.3 Other
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospitals and Clinics
12.5.2 Pharmaceutical Company
12.5.3 Research Center
12.5.4 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Oncology Radiopharmaceutical Market Analysis, Insights and Forecast, 2026-2035
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Oral Drugs
13.4.2 Intravenous Drugs
13.4.3 Other
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospitals and Clinics
13.5.2 Pharmaceutical Company
13.5.3 Research Center
13.5.4 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Oncology Radiopharmaceutical Market Analysis, Insights and Forecast, 2026-2035
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Oral Drugs
14.4.2 Intravenous Drugs
14.4.3 Other
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hospitals and Clinics
14.5.2 Pharmaceutical Company
14.5.3 Research Center
14.5.4 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Oncology Radiopharmaceutical Scope:
|
Report Data
|
Oncology Radiopharmaceutical Market
|
|
Oncology Radiopharmaceutical Market Size in 2025
|
USD XX million
|
|
Oncology Radiopharmaceutical CAGR 2025 - 2032
|
XX%
|
|
Oncology Radiopharmaceutical Base Year
|
2024
|
|
Oncology Radiopharmaceutical Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Novartis, Chimeric Therapeutics Limited, Fusion Pharma, Lantheus Medical lmaging, Inc., NanoMab, NuView Life Sciences., PentixaPharm GmbHPrecirix, RadioMedix, RayzeBio, Telix Pharmaceuticals Limited, Theragnostics Ltd, Vect-Horus.
|
|
Key Segments
|
By Type
Oral Drugs
Intravenous Drugs
Other
By Applications
Hospitals and Clinics
Pharmaceutical Company
Research Center
Other
|
